SEIS INVEST OPPORTUNITY · SOPHISTICATED & HNW INVESTORS
A large, regulated, fast-growing market with no compliance-first platform for cross-border B2B procurement. Pharmiva is building it — connecting clinics to verified suppliers across Germany, the Netherlands, Poland and the United Kingdom.
HMRC SEIS Advance Assurance applied for · Subscription documents via SeedLegals
SEIS Raise
Pre-Money
Equity
Income Tax Relief
European medical aesthetics is growing fast and professionalising under tightening regulation — yet clinics still have no compliant, cross-border way to procure injectables and devices. The backdrop is public; the platform is missing
UK practitioners across 5,589 clinics, delivering ~900,000 botulinum toxin treatments a year.
UK market in 2026, forecast to 2028 at 10.2% CAGR — Europe’s most mature aesthetics market
European aesthetics market by 2028 — thousands of clinics across DE, NL and PL with no compliant digital B2B procurement platform.
Growth in male treatments since 2021; the 26–34 cohort is now the largest patient group.
European medical aesthetics is growing fast and professionalising under tightening regulation — yet clinics still have no compliant, cross-border way to procure injectables and devices. The backdrop is public; the platform is missing
Clinics source from unverified suppliers via phone, trade shows and personal contacts — with no compliance layer in the procurement chain.
There is no single, always-on marketplace where clinics across multiple markets can compare supplier-verified products and prices.
Botulinum toxin is a prescription-only medicine across the EU; verifying prescriber credentials at the point of order is largely manual.
Without licensed, transparent cross-border supply, clinics are exposed to grey-market imports and the regulatory risk that follows.
Pharmiva is the technology layer for compliant B2B aesthetic procurement,
operating through licensed wholesale infrastructure. Clinics get one verified,
auditable channel; suppliers get reach. Compliance is built into the order flow,
not bolted on.
The detail of how Pharmiva’s platform and its licensed infrastructure fit together — the structure, the defensibility, and why it is difficult to replicate — is set out in the investor deck, available to qualifying investors on request.
Every regulatory step rewards an operator built around compliance from day one. Tightening rules turn non-compliant supply chains into licence risk — and increase the value of a platform that makes compliance frictionless. Compliance is the moat, not the cost.
The raise is structured under the Seed Enterprise Investment Scheme, with attractive reliefs for eligible UK investors. HMRC Advance Assurance has been applied for; SEIS3 certificates are issued after the qualifying trading period.
Income Tax Relief
After 3 years
Max loss per £1
IHT relief after 2 yrs
Full investment terms, valuation rationale, use of proceeds, roadmap and the complete risk summary are set out in the investor deck and Information Memorandum — released to investors who qualify and register below. SEIS reliefs depend on individual circumstances and HMRC approval, and may be withheld or withdrawn.
Purpose-built platform for supplements and aesthetics products.
Structured onboarding to enhance vendor credibility and trust.
Optimised search and filtering for efficient product discovery.
Analytics tools to improve vendor performance and conversions.
Commission, subscriptions, and advertising revenue streams integrated.
Clear product information supporting confident purchasing decisions.
Built for sustainable growth within evolving regulatory environments.
First-time angel investors
Experienced angels
High-conviction angels
Complete the short investor form to express interest in the Pharmiva SEIS raise and receive the investment pack, including the deck, financials, and key terms.
Assess the opportunity, conduct your due diligence, and speak directly with the founding team to clarify valuation, allocation, and EIS eligibility before confirming your commitment.
Sign the subscription documents, transfer funds, and receive confirmation of your shareholding along with EIS documentation and ongoing investor updates.
Learn More About The Process
The full opportunity — deck, Information Memorandum and terms — is a financial promotion directed only at qualifying investors. Register your interest and confirm your investor status to receive it.
Find clear answers to common investor questions about the Pharmiva opportunity, including our marketplace model, growth strategy, SEIS benefits, and investment process.
Pharmiva is a compliance-first B2B marketplace connecting aesthetic clinics to verified suppliers of injectables and medical devices across the UK, Germany, the Netherlands, and Poland — with compliance built directly into the order flow.
Aesthetic clinics currently source products through fragmented, unverified channels. Pharmiva replaces that with a single, auditable procurement platform operating through licensed wholesale infrastructure.
A built-in telemedicine layer verifies prescriber credentials before any prescription-only product is dispatched, removing the manual checks clinics currently rely on.
All suppliers undergo KYC and vendor verification. Every order flows through licensed infrastructure with a full audit trail, giving clinics a defensible, regulatory-compliant procurement record.
Injectables and medical aesthetic devices sourced from verified, licensed suppliers — all carrying full compliance documentation.
Pharmiva is raising £250,000 under SEIS at a £2.25 million pre-money valuation, representing 10% equity.
Eligible UK investors can receive 50% income tax relief, CGT-free gains after 3 years, up to 100% IHT relief after 2 years, and a maximum loss exposure of around 38.5p per £1 invested. Reliefs depend on individual circumstances and HMRC approval.
Register your interest on the website to receive the full investor deck and Information Memorandum. This raise is open to sophisticated and high-net-worth investors only.
Have questions or need expert guidance? Connect with our team for tailored financial solutions and personalised support to meet your goals
261 Bolton Road, 2839 Davenport House, Bury, United Kingdom, BL8 2NZ
The Compliance Technology Layer For European Aesthetics.
Copyright © PHARMIVA LTD 2026 All Rights Reserved.
